Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026
Antibiotic Duration after Debridement and Implant Retention for Early Postoperative Spinal Implant Infections: A Multicenter Cohort Study.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Tai Don Bambino Geno, Poehlein Emily, O'Neil Jessica C, Nelson Sandra B, Tande Aaron J, Corvino Daniela De Lima, Ritter Alaina S, Aronson Jenny, Certain Laura, Furukawa Daisuke, Tatara Alexander M, Green Cynthia L, Abdalla Tarek, Fleece Molly E, Tobert Daniel G, Erickson Melissa, Seidelman Jessica, SPIRIT Team
Аннотация
BACKGROUND: Postoperative spinal implant infections (PSII) are a serious complication of instrumented spinal fusion. Although debridement with implant retention is standard for early infection, the optimal duration of antimicrobial therapy remains uncertain.
METHODS: We conducted a multicenter retrospective cohort study across ten U.S. academic centers, including adults with early PSII (≤90 days after fusion surgery) from 2017 to 2021. We excluded patients who experienced treatment failure within 6 weeks of debridement. The primary outcome was treatment failure. Antibiotic therapy effect was analyzed as a time-varying exposure using adjusted Cox proportional hazards models. Secondary analyses included 12-week landmark and clone-censor-weighted models to compare durations ≤12 weeks versus >12 weeks.
RESULTS: 116 patients out of 499 (23.2%) experienced treatment failure during a median follow-up of 3.2 years. Among patients who remain failure-free six weeks from debridement, being on antibiotics was not associated with treatment failure (adjusted hazard ratio [aHR] 0.71, 95% confidence interval [CI] 0.48-1.07; p = 0.10). In a 12-week landmark analysis limited to 359 patients who were not on indefinite suppressive antibiotic therapy, treatment durations >12 weeks did not significantly reduce the risk of failure (aHR 1.01, 95% CI 0.62-1.64; p = 0.99). Results were consistent in the clone-censor-weight sensitivity analysis (aHR 0.85, 95% CI 0.62-1.16; p = 0.30).
CONCLUSIONS: Prolonged antibiotic therapy was not associated with improved outcomes in early PSII managed with debridement and implant retention. These results support shorter, individualized antibiotic courses in patients with adequate surgical source control.
METHODS: We conducted a multicenter retrospective cohort study across ten U.S. academic centers, including adults with early PSII (≤90 days after fusion surgery) from 2017 to 2021. We excluded patients who experienced treatment failure within 6 weeks of debridement. The primary outcome was treatment failure. Antibiotic therapy effect was analyzed as a time-varying exposure using adjusted Cox proportional hazards models. Secondary analyses included 12-week landmark and clone-censor-weighted models to compare durations ≤12 weeks versus >12 weeks.
RESULTS: 116 patients out of 499 (23.2%) experienced treatment failure during a median follow-up of 3.2 years. Among patients who remain failure-free six weeks from debridement, being on antibiotics was not associated with treatment failure (adjusted hazard ratio [aHR] 0.71, 95% confidence interval [CI] 0.48-1.07; p = 0.10). In a 12-week landmark analysis limited to 359 patients who were not on indefinite suppressive antibiotic therapy, treatment durations >12 weeks did not significantly reduce the risk of failure (aHR 1.01, 95% CI 0.62-1.64; p = 0.99). Results were consistent in the clone-censor-weight sensitivity analysis (aHR 0.85, 95% CI 0.62-1.16; p = 0.30).
CONCLUSIONS: Prolonged antibiotic therapy was not associated with improved outcomes in early PSII managed with debridement and implant retention. These results support shorter, individualized antibiotic courses in patients with adequate surgical source control.